Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

BACKGROUND AND AIM: Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cardiovasc Diabetol
Main Authors: Lundgren, Julie R., Færch, Kristine, Witte, Daniel R., Jonsson, Anna E., Pedersen, Oluf, Hansen, Torben, Lauritzen, Torsten, Holst, Jens J., Vistisen, Dorte, Jørgensen, Marit E., Torekov, Signe S., Johansen, Nanna B.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6778378/
https://ncbi.nlm.nih.gov/pubmed/31586493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0937-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki